If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
138
results.
Updated on
20/08/2026 [07:52:00]
Results 50 to 75 of 138
Absstract of: US20260183273A1
The invention relates to the therapeutic application of multifunctional compounds that act as α2 adrenoreceptor antagonists and cholinesterase inhibitors for the treatment of Alzheimer's disease and other neurodegenerative diseases, or the concomitant use of a mixture of an α2 adrenoreceptor antagonist and a cholinesterase inhibitor to achieve the same effect.
Absstract of: US20260184770A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Absstract of: US20260183276A1
0000 The subject invention pertains to compositions comprising Poly(A) RNA polymerase D5 (PAPD5) small molecule inhibitors and methods of using said compositions to treat Huntington's Disease (HD). The PAPD5 small molecule inhibitor is, for example, BCH001 and RG7834. The PAPD5 small molecule inhibitor can mitigate the neuronal defects and cell death in HD.
Absstract of: US20260183407A1
0000 The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, CLKI, CLK2, CLK3, CLK4, and HASPIN. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, and HASPIN, such that the one or more kinases is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of the one or more kinases. The bifunctional compounds serve as therapeutics for the treatment of Alzheimer's disease, down syndrome, diabetes, an autoimmune disease, an inflammatory disorder (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer), a viral infection (e.g., SARS-COV-2 infection (e.g., COVID-19)), and other diseases.
Absstract of: US20260185159A1
0000 Among the various aspects of the present disclosure is the provision of a method of detecting, preventing, reversing, treating, or delaying the onset of a neurological disease (e.g., adult-onset neurological diseases, Alzheimer's disease, Parkinson's disease, Frontotemporal dementia).
Absstract of: WO2026142675A1
The invention relates to the development of an active agent increasing the activity of α-carbonic anhydrase (hCA) enzymes, having the potential to be used in the treatment of Alzheimer's and certain neurodegenerative disorders.
Absstract of: US20260183333A1
The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
Absstract of: US20260185095A1
Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.
Absstract of: US20260184772A1
The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.
Absstract of: US20260183274A1
0000 Provided is a 3-phosphoinositide-dependent protein kinase 1 (PDK1) modulator compound. The PDK1 modulator compound is provided as a compound represented by chemical formula 1, or a solvate, hydrate, prodrug, stereoisomer or pharmaceutically acceptable salt thereof, and regulates, inhibits or antagonizes the activity of PDK1, and thus can be used for anticancer, antifibrosis, anti-aging and reverse aging, or treatment or prevention of Alzheimer's disease or autoimmune disease. In addition, the present invention provides a composition for anticancer, antifibrosis, anti-aging and reverse aging, or treatment, prevention or alleviation of Alzheimer's disease or autoimmune disease, containing the PDK1 modulator compound and a salt thereof as active ingredients, and provides a method, in which the compound and a salt thereof are administered to a subject, for anticancer, antifibrosis, anti-aging and reverse aging, or treatment, prevention or alleviation of Alzheimer's disease or autoimmune disease.
Absstract of: WO2026138307A1
New use of 1-amino-3,5-dimethyladamantane hydrochloride in treating or preventing cognitive impairment, reducing microglia in the cortex and hippocampus, reducing neuron loss in the cortex and hippocampus, and ameliorating the mitochondrial dysfunction state. The cognitive impairment includes cognitive impairment in systemic lupus erythematosus, Parkinson's disease, lateral sclerosis, stroke, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, attention deficit hyperactivity disorder, sepsis-related encephalopathy, or mild cognitive disorder. The present application also provides a corresponding drug and a treatment or prevention method.
Absstract of: WO2026139910A1
The invention relates to stable oral formulations of pimavanserin or its pharmaceutically acceptable salts, provided in the form of ready-to-use liquids, powders for reconstitution, orally dispersible tablets, and kits containing pre-measured powder and a liquid vehicle for reconstitution. These formulations are stable for longer periods and are palatable, thereby improving patient compliance and adherence in the treatment of psychosis associated with Parkinson's disease.
Absstract of: US20260183416A1
0000 A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.
Absstract of: EP4768587A1
The present invention provides siRNA, peptide oligonucleotide drugs, and their applications for suppressing the expression of the amyloid precursor protein (APP) gene in human cells. The siRNA exhibits potent activity in inhibiting APP expression. Through appropriate modifications, its ability to silence the target is enhanced while reducing off-target activity. The described siRNA and its conjugates hold promise for clinical application in the prevention and treatment of diseases associated with the APP target, including cerebral amyloid angiopathy (CAA), early-onset familial Alzheimer's disease (EOFAD), or Alzheimer's disease (AD).
Absstract of: CN122121896A
The present disclosure relates to methods and compositions for the treatment of Parkinson's disease, which is a neurodegenerative disorder characterized by loss of dopaminergic neurons. In particular, the present disclosure provides formulations of dopaminergic cells that are demonstrated to have a therapeutic effect on motor and non-motor symptoms of the disease.
Absstract of: WO2025106603A1
The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's Disease. Such methods entail administering a pharmaceutical composition comprising an immunogenic fragment of Aβ capable of inducing a beneficial immune response in the form of antibodies to Aβ. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.
Absstract of: EP4768479A1
Compounds represented by the following structure, or tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs thereof. Said compounds can be used as AT2R agonists.
Absstract of: EP4512403A1
Described is a pharmaceutical composition comprising an antagonist/inhibitor of neuropeptide B/W receptor (NPBWR1) for use in in a method of treating, ameliorating or preventing a mood disorder/affective disorder and/or chronic stress and/or anxiety disorders and/or Parkinson's disease. Moreover, described is a pharmaceutical composition comprising an agonist/activator of neuropeptide B/W receptor (NPBWR1) for use in in a method of treating, ameliorating or preventing a bipolar affective disorder (ICD-10 F31) during the manic phase, appetitive disorders, preferably anorexia or bulimia. Further, described is a method for assessing the activity of a candidate molecule suspected of being an antagonist/inhibitor or an agonist/activator of NPBWR1.
Absstract of: EP4768503A1
Provided is an antibody or an antigen-binding fragment thereof that binds to β-Amyloid (Aβ). Further provided are a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a cell comprising the antibody or the antigen-binding fragment thereof or nucleic acid thereof, a pharmaceutical composition, a kit, and the use of the antibody or the antigen-binding fragment thereof in the preparation of a drug used for treating or preventing a disease caused by abnormal accumulation or deposition of Aβ in subjects.
Absstract of: KR20260102258A
본 발명은 황기, 산수유, 당귀 및 오미자 추출물로 이루어진 생약복합 추출물을 유효성분으로 함유하는 파킨슨병의 예방, 개선 또는 치료용 조성물에 관한 것으로, 본 발명의 생약복합 추출물이 황기, 산수유, 당귀 및 오미자 단독 추출물에 비해 PC12 신경 세포에서 MPP+ 신경독성 처리 후 세포 보호 효과가 있고, 신경 세포의 활성산소종(reactive oxygen species, ROS) 생성을 억제시킬 뿐만 아니라, MPTP로 유도한 파킨슨병 동물모델에서 운동기능을 현저하게 향상시키는 효과가 있으므로, 파킨슨병의 예방 및 치료용 의약품 또는 파킨슨병의 예방 및 개선용 건강기능식품으로 유용하게 사용될 수 있다.
Absstract of: CN122297482A
The invention discloses application of bimatoprost in preparation of a medicine for preventing and/or treating Parkinson's disease in the field of medicine reutilization. Bimatoprost is a prostaglandin F2alpha analogue, and is mainly used for glaucoma and eyelash growth at present. Researches find that bimatoprost can improve behavior disorders related to the Parkinson's disease, improve expression of melanin dopaminergic neuron related protein tyrosine hydroxylase and reduce abnormal accumulation of alpha-synuclein, and has good improvement and protection effects on the Parkinson's disease. The invention provides a new drug choice for treatment of Parkinson's disease.
Absstract of: CN122297525A
The invention discloses application of maggot oil in preparation of medicines for preventing and/or treating neurodegenerative diseases, and belongs to the technical field of biological medicines. The maggot oil disclosed by the invention is prepared by adopting supercritical CO2 extraction, the content of EPA (eicosapentaenoic acid) is 2.16 g/100g, the content of nervonic acid is 0.0104 g/100g, and the total amount of unsaturated fatty acid reaches 49.1 g/100g. The maggot oil can play a nerve protection role by inhibiting beta-amyloid protein deposition, reducing neuronal apoptosis, relieving neuroinflammation, protecting dopaminergic neurons and other pathways, and can effectively resist neuron damage caused by excitatory toxicity and oxidative stress, remarkably improve spatial learning and memory ability and relieve cognitive function decline. The invention provides an efficient and safe drug choice for prevention and treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and the like.
Absstract of: CN122297679A
The invention relates to the technical field of molecular biology, in particular to application of PRAS40 protein as an Alzheimer's disease treatment target. According to the present invention, with the combination of western blot verification, computer virtual docking, surface plasmon resonance (SPR) and other technical means, the PRAS40 protein is proved to be the key target spot affecting the AD pathological process; experimental results show that specific intervention (elimination or reduction) of the PRAS40 protein level is sufficient to significantly improve cognitive defects and pathological characteristics of AD model mice, so that a clear molecular target is provided for subsequent screening and development of novel anti-AD drugs.
Absstract of: CN122297678A
The invention relates to application of STBD1 as a target spot in treatment of Alzheimer's disease. Specifically, the invention relates to application of a reagent targeting STBD1 in preparation of drugs for treating Alzheimer's disease, and the reagent targeting STBD1 is selected from: i) a reagent for inhibiting and/or reducing the expression level of STBD1 gene and/or protein; and ii) an interference agent for the interaction of STBD1 with GABARAPL1.
Nº publicación: CN122297714A 30/06/2026
Applicant:
OUJIANG LABORATORY
\u74EF\u6C5F\u5B9E\u9A8C\u5BA4
Absstract of: CN122297714A
The invention discloses a preparation method and application of a drug-loaded fibroin preparation crossing a blood brain barrier, and relates to the technical field of biomedical materials. In order to regulate and control self-assembly of bioactive particles by using silk protein fibers, the performance of a nano delivery system is optimized, and the application value of the nano delivery system in the field of treatment of various diseases such as the Alzheimer's disease is improved. The silk protein nano-carrier specifically comprises silk protein nano-fibers, functional treatment active components and mannose/rabies virus capsid protein, the silk protein nano-fibers form nano-particles through self-assembly, and the functional treatment active components are prepared into the bioactive silk protein nano-carrier through the silk protein nano-fiber self-assembly process. The preparation method is simple in process and convenient to operate, the formed stable drug-loaded fibroin nano-delivery carrier preparation is combined with different receptors of brain microvascular endothelial cells to realize high brain entering efficiency, and a brand new thought is provided for design of the fibroin nano-delivery carrier.
BOPI
Electronic site
